Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs

Aya Hefnawy, Maya Berg, Jean-Claude Dujardin, Geraldine De Muylder

Onderzoeksoutput: Bijdrage aan tijdschriftA1: Web of Science-artikel

Uittreksel

New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.

TaalEngels
TijdschriftTrends In Parasitology
Volume33
Exemplaarnummer3
Pagina's (van-tot)162-174
Aantal pagina's13
ISSN1471-4922
DOI's
StatusGepubliceerd - 2017

Vingerafdruk Bekijk de onderzoeksthema's van 'Exploiting knowledge on <em>Leishmania</em> drug resistance to support the quest for new drugs'. Samen vormen ze een unieke vingerafdruk.

Dit citeren